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The discrimination of selffrom non-self is an integral function of the immune
system . Both class I and class II molecules of the MHC play a central role in this
discrimination in that these molecules serve as the self recognition structures for
theTCR during the presentation of foreign antigens (1, 2) . As antigen presentation
structures, the class I and class II molecules selectively bind peptides that presum-
ably are the result of intracellular degradation or "processing" (3-7) . Although the
TCR is capable ofdiscriminating self from non-self, MHC molecules do not appear
to make such a discrimination in that it is now clear that degradation of self proteins
can also result in peptides that can be bound by autologous class II (8-10) and pre-
sumably by class I molecules .
Recent studies from a number of laboratories have suggested that class I-derived
peptides can be bound by class I molecules . Examples of this include the binding
of human class I (HLA-C)-derived peptides to murine class I (H-2) molecules (11,
12), the binding ofH-2Ld-derived peptides to H-2D' or H-21)d-1 (13, 14), and the
binding of an HLA-A2-derived peptide to HLA-Aw69 (15, 16) . Although each of
these systems represents an artificial situation in which the class I molecule is ex-
posed to a peptide that it would not normally encounter, they do demonstrate the
feasibility ofclass I-derived peptides being bound by intact class I molecules . Fur-
thermore, they raise the possibility that such binding could occur normally in the
nonmanipulated animal .
We have extended these observations to the class II system in amanner that might
better reflect naturally occurring antigen processing and presentation . Specifically,
we asked whether class II molecules contain peptide sequences that are capable of
binding to their own class II or other class II alleles . We have identified synthetic
peptides based on the sequences from the polymorphic regions of the I-A' mole-
cule that bind to both I-Ak and I-Ad . These peptides competitively block the pre-
sentation ofantigen to T cell hybrids of different peptide specificities, as well ascom-
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petitively inhibit the direct binding of foreign peptides to the solubilized class II
molecules. These data support the conclusions that self peptides can be presented
by class II molecules (8, 17, 18) and also support speculations that degraded MHC
may constitute some of the determinants recognized by auto- and alloreactive T
cells (13, 15, 16, 19).
Materials and Methods
CellLines.
￿
Cell lines used in these studies were maintained in vitro in RPM11640 (Irvine
Scientific, Irvine, CA) with 10% FCS, 2 mM glutamine, 1 mM sodium pyruvate, 20 Ftg/ml
gentamicin, 5 x 10-5 M 2-ME, 100 U/ml penicillin, and 100 P,g/ml streptomycin (complete
medium). The B cell lymphoma lines CH12.LX (CH12) (20) was used as a source of I-Ak-
expressing APC and A20-1 .11 (A20) (21, 22) cells were used as a source of I-Ad-expressing
APC. The T cell hybrids used in these studies are either I-Ak restricted and specific for ei-
ther the 34-45, 46-61, or 74-96 fragment of HEL (23), or I-Ad restricted and specific for the
323-339 fragment of OVA (24). HT-2 cells (25) were maintained by passage every other day
in complete medium supplemented to 25% with an IL-2-containing supernatant.
Antigen Presentation Assay.
￿
Antigen presentation experiments were performed in 96-well
microtiter plates in a total volume of 0.3 ml containing 105 APC, 105 T cell hybridoma cells,
and 50,ul of a solution of trypsinized HEL or a synthetic peptide representing the OVA se-
quence 323-339. The amounts ofthe HEL and OVA antigens used were selected on the basis
of antigen dose-response curves for each T cell hybrid and were 10-30 ttg of HEL digest
or 100 ng of OVA (323-339). Before their addition to the antigen presentation cultures the
APC were fixed with 0.5% paraformaldehyde in PBS for 20 min and washed three times.
The ability ofa PMR peptide to competitively inhibit the presentation ofthe HEL and OVA
antigenic peptides was assessed by direct addition of 2-400 t~g of the inhibitory peptide to
the antigen presentation culture. In some experiments T cell hybridomas or fixed APC were
prepulsed with the inhibitory peptides for 4 h, washed, and added to the antigen presentation
cultures. Cell cultures were maintained at 37°C in 5% humidified C02 for 20-24 h after
which seven 80-P,l twofold serial dilutions were made for determination of IL-2 titers. 4 x
103 HT-2 cells were added to each supernatant dilution, and after 16-20 h HT-2 cell via-
bility was evaluated by visual inspection. IL-2 titers were defined as the reciprocal of the
highest twofold serial dilution maintaining 90% viability ofthe HT-2 cells. Results are presented
as units of IL-2 per milliliter of undiluted supernatant, as described by Kappler et al. (26).
Since the IL-2 titer determinant is based on serial twofold dilutions, titers that differ by a
factor of four or less are generally considered not significantly different.
T Cell Hybridomas.
￿
T cell hybridomas were made by fusing antigen-stimulated lymph node
cells from B10.A(4R) mice to BW5147 cells with polyethylene glycol (PEG 1450, 1,300-1,600
MW; Eastman Kodak Co., Rochester, NY) as previously described (27). T cell hybrids h4Ly7.5,
h4Ly50.5, and kLyLl are I-Ak restricted and specific for peptides HEL(34-45), HEL(46-61),
and HEL(74-96), respectively (23). I-Ad-restricted T cell hybrids DO-11 .10, 8DO-51.15, and
3DO-54.8 are all specific for the OVA peptide OVA(323-339) (24), although each T cell hy-
brid recognizes a different epitope on this peptide (Marrack, P., National Jewish Center for
Irttmunology and Respiratory Medicine, personal communication).
Antigen.
￿
Trypsinized HEL was produced by initially dissolving 1.5 g of native HEL in
100 ml of 8 M urea, 0.2 M 2-ME and stirring overnight at room temperature. The reduced,
denatured antigen was alkylated with 0 .3 M iodoacetic acid while maintaining the pH near
8.0 by the addition of 2 M NaOH. The antigen was subsequently dialyzed against several
changes of 5 mM Tris/HCl, pH 7.4, followed by 0.1 M (NH4)HCO3, and lyophilized. Tryp-
sinization of the denatured HEL was done at 37'C in 0.1 M (NH4)HCO3 with two addi-
' Abbreviations used in this paper: HEL, hen egg lysozyme; HEL(46-61), a synthetic peptide corre-
sponding to the sequence of lysozyme between residues 46 and 61; OVA, ovalbumin; OVA(323-339),
a synthetic peptide corresponding to the sequence ofovalbumin between residues 323 and 339; PMR,
polymorphic region.ROSLONIEC ET AL.
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tions of trypsin (1% wt/wt) (TrypsinTPCK; Cooper Biomedical, Malvern, PA) over 24 h,
followed by lyophilization.
Peptides representing the native OVA(323-339) and HEL(46-61) sequences and the seven
polymorphic regions of the I-A' molecule (Table I) were synthesized by the general solid
phase method outlined by Merrifield et al. (28) on a peptide synthesizer (model 430A; Ap-
plied Biosystems, Foster City, CA) as described by Buus et al. (29). The synthetic peptides
were purified by reverse-phase HPLC using a Vydac (Hesperia, CA) C1s semi-preparative
column and a gradient of 0-50% acetonitrile in 0.1% trifluoroacetic acid. The purified syn-
thetic peptides were analyzed for amino acid composition and their amino acid sequences
were determined; they were found to be >90% pure by these criteria.
1-A Binding Assay.
￿
I-A binding experiments were performed as described by Buus et al.
(30). I-Ak and I-Ad were affinity purified from lysates ofAKTB-lb and A20 lymphoma cells,
respectively, as previously described (29). The antigenic peptides HEL (46-61) and
OVA(323-339) were synthesized as described above with the addition of a tyrosine residue
on the amino terminus for purposes of 1251-labeling (31). Each binding assay consisted of
5-10 tkg of I-Ak or I-Ad, 10 ng (0.5 /AM) of '251-labeled peptide, and 10-1,000 [LM of the com-
petitive PMR peptides. After a 40-48-h incubation at room temperature the percent
HEL(46-61) or OVA(323-339) peptide bound was determined by G-50 column chromatog-
raphy (30).
Results
Peptides Corresponding to the Polymorphic Regions ofClass II Can Block Presentation ofAn-
tigenic Peptides to T CellHybridomas. Peptides corresponding to the seven polymorphic
regions (PMR) of the a1 and (31 domains of the I-A' molecule were synthesized ac-
cording to the sequences shown in Table I; the d allelic sequences are included for
comparison. The k and d alleles exhibit between one and five amino acid differences
in these peptides. The synthetic peptides were chosen such that the polymorphic
TABLE I
Amino Acid Sequences of I-Ak and I-Ad Potymorphic Region Peptides
' Residue numbers are based on d haplotype numbering.
$ Dashes indicate identity between the two sequences and asterisks indicate ge-
netically deleted residues.
Peptide
(residues)' Haplotype Sequence$
a-1 k DHVGSYGITVYQSP
(7-20) d ----V--T------
a-2 k PEFAQLRRFEPQGGL
(50-64) d ---G--IL-------
a-3 k LQNIATGKHNLEILTKRS
(64-81) d -----AE----G------
ti-1 k ERHFVHQFQPFCYFTN
(4-19) d -----V--KGE--Y--
13-2 k GTQRIRLVIRYIYNRE
(20-35) d --------T-------
0-3 k DAEYWNKQ'Y'LERTRAE
(57-74) d ------ S-PEI-------
0-4 k RHNYEKTETPTSLRRL
(80-95) d -----GP--S------1422
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residues tend to be in the center of the peptides with the overall length of the pep-
tides ranging from 14 to 18 amino acids each.
Each of thek haplotype PMRderived peptides was tested for its ability to inhibit
the presentation of tryptic fragments of hen egg lysozyme (HEL) to a set of T cell
hybridomas, each ofwhichis specific foradifferent HEL peptide (23) and restricted
by the I-Ak molecule. As the results in Fig. 1 show, peptides corresponding to the
first and third PMR of the Aak chain (uk-1 and ak-3, respectively) inhibit, in a dose-
dependent manner, the presentation of the HEL(34-45) peptide to the h4Ly7.5 T-
cell hybridoma (panel A), ofHEL(46-61) to the h4Ly50.5 hybridoma(panel B), and
of HEL(74-96) to the kLy-1.1 hybridoma (panel C). As shown in Fig. 1, the ak-2
peptide showed no inhibitory activity. Similarly, all peptides corresponding to the
Ask chain PMR are noninhibitory (data not shown).
To ascertain the specificity ofthese inhibitions, the full set of peptides corresponding
to the PMR of the A«k and Ask chains were tested for their ability to inhibit the
presentation of the OVA(323-339) peptides to three I-Ad restricted T cell hybrid-
omas. Although each ofthesehybridomas is specific for theOVA (323-339) peptide
(3), each exhibits a different fine specificity for the antigen as determined by trunca-
tion and amino acid substitution studies (Marrack, P., personal communication).
The data from these experiments, shown in Fig. 2, reveal the unanticipated result
that the ak-1 peptide is strongly inhibitory to the presentation of the OVA peptide
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FIGURE 1.
￿
Inhibition of I-Ak-restricted antigen
presentation by I-Ak PMR-derived peptides.
Synthetic peptides based on I-Ak PMR se-
quences ak-1 (0), cik-2 (O), crk-3 (A)were tested
fortheirabilityto inhibit thepresentation ofHEL
tryptic peptides HEL(34-45), HEL(46-61), and
HEL(74-96) to I-Ak-restricted T cell hybrids
h4Ly7.5 (A), h4Ly50.5 (B), and kLyl.l (C),
respectively. Before the antigen presentation
assays, APC (CH-12) were fixed with 0.5%
paraformaldehyde. TheHELantigenic peptides
andthe inhibitory cik peptides were present for
theduration ofthe24-h antigen presentation cul-
ture. IL-2 production wasassessed by theability
oftwofolddilutions ofculturesupernatants to sup-
port the growth ofthe IL-2-dependent cell line,
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FIGURE 2 .
￿
Inhibition of I-Ad-restricted antigen
presentation by I-Ak PMRderived peptides .
Synthetic peptides al-1 (p), al-2 (O), al-3 (A)
were tested for their ability to inhibit the presen-
tation ofOVA(323-339) to I-Ad-restrictedT cell
hybrids DO-11.10 (A), 8DO-51.15 (B), and3DO-
54 .8 (C) . Before the antigen presentation assays,
APC (A20) were fixed with 0.5% paraformalde-
hyde . The OVA peptide and the inhibitory ak
peptides were present for the duration of the 24-
h antigen presentation culture . IL-2 production
was assessed as described in Fig. 1 .
to all three hybridomas . The peptides corresponding to thePMR of the Ask chain
were noninhibitory at all doses tested (data not shown) .
Prepulsing theAPCs but not theTCell Hybridomas with PMR Peptides Blocks the Presenta-
tion ofHEL Peptides. To establish whether the inhibition of class II-mediated an-
tigen presentation byPMR peptides is homologous to that previously reported for
the class I-mediated processes (15, 16), either the APCs or the HEL-specific T cell
hybridomas were prepulsed with the Ac,k chain PMR peptides . In contrast to the
results reported for the class I-specific system in which inhibition ofcytolysis could
be blocked by prepulsing theCTL with the appropriate class I PMR peptide (16),
we found that prepulsing the I-Ak-restricted HEL-specific peptides had no effect on
the subsequent presentation of HEL peptides to the hybridomas (Fig. 3 A) . How-
ever, as shown in Fig . 3 B, prepulsing of the APC with theak-1 and txk-3 peptides
produced a degree of inhibition of antigen presentation comparable to that seen in
the direct competition experiments (see Fig. 1), whereas theCM peptide again had
no effect on the presentation of the HEL peptides.
Synthetic Peptides Corresponding to the Firstand ThirdPMR of the A,,' ChainBind Directly
to the I-A' Molecule. The most obvious explanation for the inhibition of antigen pre-
sentation observed when prepulsing theAPC but not the T cell hybridomas with
the PMR peptides is that the Aak PMR peptides bind to the I-Ak molecule itself,
therefore preventing the binding of the HEL peptides . This possibility was tested1424
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FIGURE 3 .
￿
Determination of mode of antigen
presentation inhibition by pre-pulsing Tcell
hybrids and APC with I-At PMR-derived pep-
tides . T cell hybrids (A) or fixed CH-12 APC (B)
were prepulsed with either ak-1 (M), or at'-2
(®), or a kk -3 (0), or no peptide (E) for 4 h and
then washed before use in antigen presentation
cultures . In the antigen presentation cultures
prepulsed T cell hybrids were mixed with normal
fixed APC (A) or prepulsed APC were mixed with
normal T cell hybrids (B) . HEL antigenic pep-
tides were then added to the presentation cultures
and were present throughout the 24 hour culture
period . IL-2 production was assessed as described
in Fig . 1 .
by determining the ability of the PMR peptides to compete with 1251-labeled
HEL(46-61) peptide for bindingto purified I-Ak molecules . As shown in Fig. 4 A,
the ak-1 and ak-3 peptides blocked the binding of the 1251-labeled HEL(46-61) in-
dicator peptide although not quite as efficiently as the autologous HEL(46-61) pep-
tide . Consistent with the results of the antigen presentation-inhibition experiments
(Fig . 1), the ak-2 peptide did not alter the binding of the 1251-HEL(46-61) .
Direct binding competitions were also carried out between 1251-OVA(323-339)
and thePMR peptides of the Auk chain for binding to purified I-Ad molecule . The
OVA(323-339) peptide, an immunodominant peptide in the H-2d haplotype, binds
strongly to the I-Ad molecule (3, 29, 30, 32). Nevertheless, the C1k_1 peptide suc-
cessfully competes on a mole for mole basis with the 1251-OVA(323-339) peptide for
binding to purified I-Ad molecules, as shown in Fig . 4 B. Modest inhibition of
binding of the 1251-OVA(323-339) peptide is also obtained using the highest con-
centration of the ak-3 peptide (see Fig, 4 B) . These results closely parallel the an-
tigen presentation results in Fig . 2 in which theak-1 peptide strongly inhibits pre-
sentation ofthe OVA(323-339) peptide to all three hybridomas tested and the C1k_3
peptide is weakly inhibitory to thepresentation ofantigen to theDO-11.10 hybridoma.
In both the I-Ad and the I-A' binding experiments the G-50 column chromatog-
raphy data gave no indication of the existence of aPMR peptide-antigenic peptide
complex (data not shown) .Y
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FIGURE 4.
￿
Inhibition ofantigenic peptide bind-
ingby I-Akand I-Mwith peptides derived from
thePMR of I-A' . Detergent solubilized, affinity
purified I-Ak and I-M were tested for their
ability to bind
1251-HEL(46-61) (A) and r=5I-
OVA(323-339) (B), respectively, in the presence
of varying concentrations of the txk-1("), ak-
2(/), of
k-3(") peptides or homologous unla-
beled HEL(46-61) (O,A) andOVA(323-339) (O,
B) peptides . After 48-h incubations of I-A and
peptides, the percent of labeled peptide bound
to the I-A molecule was determined by frac-
tionation over a G-50 Sephadex column . The
percent of labeled peptide bound in theabsence
of peptide inhibitors was 14.3% for I-Ak and
HEL(46-61) and 16.8% for I-M and OVA(323-
339) .
Discussion
A number oflaboratories, usingtechniques from immunology, biochemistry, and
x-ray crystallography, have produced data that suggest that the molecular basis for
"MHC-restricted" presentation of antigen to T cells is the direct physical binding
of proteolytic fragments of the antigen to the appropriate MHC molecule ("restric-
tion element"), followed by the recognition ofthis complex by the appropriate antigen-
specific, MHC-restricted TCR. While this model is a currently accepted paradigm
for antigen-specific T cell recognition, a number of questions remain about other
physiologically relevant and presumably related forms of T cell recognition, such
as TCR-mediated positive and negative selection in the thymus and recognition of
alloantigens by peripheralTcells .A significant portion oftheuncertainty surrounding
these latter processes derives from uncertainty over the exact ligand for the TCR,
i.e., does theTCR recognize onlyMHC withboundpeptideor canMHC molecules
devoid of peptide also be recognized? If such "empty" MHC molecules exist and
are recognized, in which compartments do they exist and what is the physical basis
for their recognition by TCR that normally recognize a complex between peptide
and MHC? Alternatively, ifMHC molecules always have a peptide in the antigen
binding cleft, what proportion of MHC molecules are occupied by self peptides,
and is there a subset of selfpeptides, such asMHC-derived peptides, that are prefer-
entially bound? Clearly, the answers to these questions will have a major impact
on the issues of thymic selection and alloreactivity .
The pioneering studies of Babbit et al . (33) demonstrated that self peptides can
be bound by class II MHC molecules, and the more recent studies by Lorenz and
Allen (8) have provided compelling evidence that this process can occur in vivo, at1426
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least for hemoglobin or peptides derived from it . Based on these observations and
therelated observations that peptides derived from one classImolecule canbebound
andpresented by another class I molecule (11-13, 15), we decided to explore whether
a given class IIMHC molecule could bind peptides derived from its own sequence .
Ifthis should prove to be the case, it would raisethe possibility that what had previ-
ously been interpreted as the binding ofTCR to an "empty" class II molecule was
in fact the binding ofTCR to a class II molecule that had bound aproteolytic frag-
ment derived from its own sequence.
The experiments reported here demonstrate unequivocally that the class II mole-
cule I-Ak can bind synthetic peptides («k-1 and ak-3) that consist of sequences de-
rived from the I-Ak molecule itself. This binding was measured by the functional
inhibition of the presentation of immunodominant HEL peptides to HEL-specific
T cells by the synthetic peptides and by the inhibition of direct binding of the
HEL(46-61) peptide to the I-Ak molecule by the same peptides that caused inhibi-
tion of antigen presentation . Of equal importance however are the results demon-
strating that an I-Ak-derived peptide (ak-1) can bind to the I-Ad molecule . These
observations raise the possibility that the processing and presentation of polymorphic
MHC molecules or perhaps of any polymorphic molecule may play a role in the
generation of alloantigenic determinants . In addition, the direct binding data sug-
gest that the affinity of interaction between the I-A' and I-Ad molecules and the
I-A'-derived peptides can be quite high, perhaps on the order of 10 -5M based on
the reported Kd = ti2 x 10-6M for the binding of HEL(46-61) to the I-Ak mole-
cule (33) .
Our results are consistent with the recent data ofMurphy et al . (34), which these
authors prefer to interpret as the serological detection ofan I-E-derived peptide bound
to the I-Ab molecule. Assuming that the preferred interpretation of Murphy et al .
is correct, this would constitute another example of a self class II-derived peptide
binding to a self class II molecule although of a different isotype than the bound
peptide . The work ofMurphy et al . takeson added significance because thecomplex
appears to be expressed in the thymic medulla but not in the thymic cortex, raising
the possibility that it could play a role in negative selection of potentially autoreac-
tive cells in the thymus (34) .
Our results contrast with the results of Clayberger et al . (16) in which an HLA-
A2-derived peptide (A2.56-69, containing residues 56 to 69 and corresponding ap-
proximately to theak-3 PMR peptide of the I-Ak molecule) was found to modulate
the response of alloreactive CTL. Surprisingly this single peptide exhibited either
inhibitory or stimulatory activity when used with aCTL clone (A2/B17) specific
foran epitope shared between HLA-A2 and HLA-B17 . Pretreatment ofHLA-Aw69
expressing cells with the A2 .56-69 peptide sensitized them for lysis by the A2/B17
clone . The authors interpret this result as an indication that the bindingoftheA2.56-69
peptide by the HLA-Aw69 molecule generated an epitope normally associated with
the HLA-A2 or B17 molecule . This interpretation is consistent with the interpreta-
tion we havemade of our results, except that Clayberger et al. designed theirreadout
to detect the generation ofan epitope throughthebinding of theMHC peptide rather
than disruption of an indicator epitope consisting of foreign peptide plus MHC
molecule .
The second function of this peptide is to inhibit the lysis ofHLA-A2 or HLA-B17ROSLONIEC ET AL.
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expressing targets by the A2/B17 CTL clone. Had this inhibition been the result
of peptide competition for the A2 or B17 binding cleft, then this result would have
been analogous to the results reported here. However, the Clayberger results differ
in one important regard: the inhibition of cytolysis is obtained by pretreating the
T cell and not the target cells with the peptide. This result implies that the A2.56-69
peptide is interacting directly with the TCR and preventing the successful interac-
tion of TCR with the complex of HLA-A2 (or HLA-B17) and some self peptide.
It seems unlikely that a peptide consisting of only 14 amino acids could bind to the
TCR with sufficient affinity to prevent the competitive binding of the class I mole-
cule/peptide complex-a protein/protein interaction that most likely involves con-
tacts spread over the entire top surface of the class I molecule (35) and entails a
potential contact surface of 600-700 A2 (36). However, at the present time no other
straight-forward explanation exists for the observation.
We do not ascribe any significance to the observation that two of our three a
chain-derived peptides bound to the I-A' molecule, while none of the four /3
chain-derived peptides bound. The peptides used in the present study were chosen
to include most of the polymorphic residues of the al and (31 domains in such a
waythat the polymorphic residues are located toward the center of a given synthetic
peptide. This arbitrary choice of peptide design may have coincidentally selected
a chain peptides that could bind whileproducing/3 chain peptides in whichthemin-
imal binding sequences have been disrupted. A much more comprehensive set of
overlapping peptides would have to be synthesized for each chain before one could
conclude that the a and /3 chains differ significantly in their content of sequences
that could be bound by the I-A' molecule.
Our studies also provide some limited insight into the mechanism of allotypic
recognition although they fall short of providing a definitive answer. The demon-
strable bindingofclass II-derived peptides to class II molecules suggests that allore-
activity could consist, at least in part, of the reaction to class II molecules that have
bound classII or MHC-derived peptides. This model is satisfying in the physicochem-
ical sense because it requires that the TCR always bind an MHC molecule with
an occupied cleft whetherit is displaying antigen-specific reactivity or alloreactivity
rather than thebindingofmoleculeswith an occupied cleft in thefirstcase and"empty"
molecules in the second. However, because of the high frequency of alloreactive T
cells for a given class II specificity, it seems unlikely that only class II-derived pep-
tides are involved in this process. The genetic studies of alloreactivity carried out
to date do not allow the discrimination between binding of a class II-derived pep-
tide from the same allele as the class II "restriction element" and the binding of a
nonpolymorphic, non-MHC-encoded self peptide. Resolution of this issue would
requirethe isolationand structural characterization oftheendogenous peptides bound
by aclass II moleculeson APC isolated from spleen andlymphnodesofintact animals.
While this experiment has not been reported, Buus et al. (37) have examined the
set of peptides bound by the I-Ad and I-Ed molecules of the A20 B cell lymphoma
grown in tissue culture. This early characterization revealed amarked heterogeneity
in the size and hydrophobicity of bound peptides but provided no further character-
ization. Nonetheless, this preliminary characterization tendsto suggest that the en-
dogenous peptides that are bound by class II molecules are derived from more than
a single molecule or even a restricted set of molecules. However, until detailed se-1428
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quence characterization is carried out on the endogenously bound peptides, it will
be unclear how many proteins contribute peptides to the bound set and whether
a subset of these proteins, e.g., the MHC molecules, contribute a disproportionate
share of peptides .
The results obtained with the a'-1 and a'-3 peptides in the present study suggest
that they fulfill the basic prerequisite for antigenicity, i.e ., they can be bound by a
class II molecule with reasonably high affinity. We are currently in the process of
evaluating the immunogenicity of these peptides and the role they mayplay in auto-
reactivity and alloreactivity .
Summary
Seven synthetic peptides corresponding to the polymorphic regions of thea and
/3 chains of the I-A' molecule were examined for their ability to inhibit the presen-
tation of foreign antigens to antigen-specific, I-A-restrictedT cell hybridomas . Two
ofthe peptides, representing the sequences found in the first and third polymorphic
regions(PMR) of the Aak chain (a'-1 and al-3) were capable of inhibiting the pre-
sentation of three different HEL-derived peptide antigens to their appropriate T
cells. In addition, theak-1 peptide inhibited the presentation of the OVA(323-339)
immunodominant peptide to the I-Ad-restricted T cell hybridomas specific for it .
Prepulsing experiments demonstrated that thePMR peptides were interacting with
theAPC and not with the T cell hybridomas . These observations were confirmed
and extended by the demonstration that theak-1 andak-3 peptides blocked the di-
rect binding of HEL(46-61) to purified I-A' and that the ak-1 peptide blocked the
binding of OVA(323-339) to I-Ad . The binding competition experiments suggest
that the ak-1 peptide binds to the I-Ak molecule from which it was derived with a
Kd ti 10-5 M, while theak-3 peptide binds slightly less well . These combined data,
suggesting that class II-derived peptides can bind to MHC class II molecules, in-
cluding the autologous molecule from which they are derived, have important im-
plications for the molecularbasis of alloreactivity and autoreactivity. Further, they
suggest a possible mechanism by which selecting elements, involving only MHC
molecules, may be generated in the thymus .
Receivedfor publication 18 December 1989 .
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